Discover-1

A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti -Tumor Necrosis Factor (TNF) Alpha Agent(s)

GuselkumabCompletedCompletedPhase 3Open NCT03162796 on ClinicalTrials.gov ↗

Population

Loading…

Intervention

Loading…

Comparator

Loading…

Loading…